FDA Brief

Warning letters Drugs

FDA warning letter to

Armstrong County Memorial Hospital

MediumIssued Oct 29, 2024Posted Nov 5, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.

What happened

FDA inspected the Armstrong County Memorial Hospital Institutional Review Board (IRB) from November 2, 2023, to November 8, 2023. FDA found the IRB did not prepare, maintain, and follow required written procedures and did not keep adequate meeting minutes, including missing attendance for a May 18, 2021 meeting and missing vote counts for a September 15, 2020 meeting. FDA also said the IRB’s response about closing and transferring responsibilities to another IRB lacked enough detail.

What FDA found

  1. The IRB failed to follow, and to prepare and maintain documentation of, written procedures for reporting its findings and actions to investigators and the institution.

    21 CFR 56.108(a)(1); 21 CFR 56.115(a)(6)
  2. The IRB failed to follow, and to prepare and maintain documentation of, written procedures for deciding which projects need review more often than annually and which need verification from sources other than the investigator.

    21 CFR 56.108(a)(2); 21 CFR 56.115(a)(6)
  3. The IRB failed to follow, and to prepare and maintain documentation of, written procedures to ensure changes in approved research are not started without IRB review and approval except to eliminate immediate hazards.

    21 CFR 56.108(a)(4); 21 CFR 56.115(a)(6)
  4. The IRB failed to follow, and to prepare and maintain documentation of, written procedures for prompt reporting to the IRB, institutional officials, and FDA of unanticipated problems, serious or continuing noncompliance, or suspension or termination of IRB approval.

    21 CFR 56.108(b); 21 CFR 56.115(a)(6)
  5. The IRB’s May 18, 2021 meeting minutes did not document which members attended when the IRB reviewed continuing review for five FDA-regulated studies.

    21 CFR 56.115(a)(2)
  6. The IRB’s September 15, 2020 meeting minutes did not document the vote on actions taken, including the number of members voting for, against, and abstaining, for a humanitarian-use device study.

    21 CFR 56.115(a)(2)

What FDA wants

Within 15 business days, FDA asks the hospital to notify it in writing of actions taken or planned and to provide a timeline and process for transferring IRB responsibilities to another registered IRB. FDA also asks for written procedures for IRB functions and operations and for meeting minutes until the transfer.

Who should pay attention

  • clinical research sponsors using this IRB
  • hospitals transferring IRB oversight
  • IRB staff and human-subject protection offices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk